Company intelligence / Profile preview

Tensar

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Tensha Therapeutics was a clinical-stage biotechnology company focused on developing small molecule inhibitors of the BET (Bromodomain and Extra-Terminal) family of proteins for the treatment of cancer and other diseases. The company's lead candidate, TEN-010, was a potent and selective BET inhibitor that showed promise in treating NUT midline carcinoma and other solid tumors. Tensha was founded based on the pioneering research of Dr. James Bradner and was acquired by Roche's Genentech unit in 2016 to bolster its oncology pipeline. The acquisition was valued at up to $535 million, including an upfront payment and potential milestone payments.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Genentech

Beyond the preview

Go deeper on Tensar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tensar.

Explore the full profile